The hypothesis that lymphocytotoxic antibodies are associated with neuropsychiatric involvement in systemic lupus erythematosus (NP-SLE) is re-evaluated in this study. In 
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterised by diverse circulating autoantibodies.' The latter may be defined functionally-for example, lymphocytotoxic antibodies,2 3 or immunochemically.4 Associations between central nervous system disease in SLE and neurone reactive or lymphocyte/brain cross-reactive antibodies have been observed in a number of studies, suggesting a possible pathogenic role for these autoantibodies in the neuropsychiatric complications of SLE (NP-SLE). Evidence in support of this idea is the common diffuse clinical presentation of NP-SLE, the virtual absence of histopathologically documentable vasculitis within the brain at necrospy of patients with NP-SLE.," 12 and the documentation of an array of shared cell membrane antigens between lymphocytes and neurones (reviewed in ref 13) .
Central nervous system involvement in lupus is manifested by a spectrum of neurological and psychiatric disorders, ranging in severity from florid psychosis, hemiparesis, or chorea to mild paraesthesia or ill defined mood alterations. '"8
The neuropsychiatric complications of SLE are typically diagnosed when such heterogeneous neurological or psychiatric features cannot be attributed to other causes." 19 20 Attempts to classify NP-SLE systematically have been made, '4 15 21 but in general the variability of these complications and lack ofwidely recognised specific diagnostic criteria make both case definition and associations with putative aetiological factors, such as autoantibodies, problematic. We have endeavoured to categorise our patients with SLE systematically according to neuropsychiatric involvement using a classification"-" which is an extension and modification of that proposed by Kassan and Lockshin. 4 This paper reports a cross-sectional analysis of 31 and most reports ascribe lymphocytotoxic antibodies to sera which kill more than 20% of a given panel lymphocyte preparation in the presence of complement. In our experience, difficulty may arise in reliably distinguishing such minor degrees ofcytotoxicity from control results and consequently we used more exacting criteria in the assessment of lymphocytotoxic antibody activity. Also, unless the target lymphocytes killed in the assay show a broad range of HLA specificities it is likely that alloantibodies, related to prior blood transfusion or pregnancies, will be detected and contribute to an apparently high prevalence. With our criteria for lymphocytotoxic antibodies, we recorded a prevalence of 28% in 98 consecutive unselected patients. Examination of HLA specificities and autoreactivity (table 3) suggests that to a great extent autoantibodies rather than alloantibodies are being detected in this study.
Specific associations between lymphocytotoxic antibodies and central nervous system involvement in SLE have been reported. 6 40 In this study a specific positive association between cognitive dysfunction and serum lymphocytotoxic antibodies was found (table 4). The specificity of this association is emphasised by the finding that it does not seem to be related to either overall systemic disease activity or to other organ system involvement in SLE ( 4 Finally, a striking association between lupus psychosis and autoantibodies directed at a ribosomal P protein has also recently been described.45 Thus an association between cognitive dysfunction and lymphocytotoxic antibodies may imply functional or anatomical localisation of lymphocyte/ brain cross-reactive antigens in the brain, a concept supported by our recent delineation of a specific cognitive deficit in lymphocytotoxic antibody positive patients with SLE.27
A large variety of non-specific cognitive and personality problems have been noted in patients with SLE, and some of these features may be related to the high prevalence of cognitive impairment found in these subjects, particularly those without clinically evident nervous system disease. 22 The observations in this study suggest that neurocognitive evaluation should be included together with neuronal autoantibodiesl' 13 
